Biocartis, a Lausanne, Switzerland-based molecular diagnostics company developing and commercializing platforms and clinically relevant oncology assays, completed a €34,5m (approximately $45m, CHF 42m) Series D equity funding.
The round was led by the Flemish investment company PMV (using its TINA-fund), with participation from RMM, Valiance, Debiopharm Group, Korys (investment holding of the Colruyt family), Philips, Johnson & Johnson Development Corporation (JJDC), the family office of Dr Paul Janssen, Luc Verelst, Benaruca (Rudi Pauwels, founder of Biocartis) and New Rhein Healthcare (Greg Parekh, Biocartis CEO).
The company intends to use the capital to continue to develop its oncology tests, validate, register and launch the Apollo platform, and grow its commercial presence.
In conjunction with the funding, Roald Borré, representing PMV, will join Biocartis’ Board.
The company is led by Greg Parekh, CEO, and chairman and founder Rudi Pauwels.